Last reviewed · How we verify
Vehicle versus NB-001
NB-001 is a vaccine.
NB-001 is a vaccine. Used for Influenza.
At a glance
| Generic name | Vehicle versus NB-001 |
|---|---|
| Sponsor | NanoBio Corporation |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
NB-001 is a vaccine that works by stimulating an immune response against a specific target, but the exact mechanism is not publicly disclosed.
Approved indications
- Influenza
Common side effects
- Injection site pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vehicle versus NB-001 CI brief — competitive landscape report
- Vehicle versus NB-001 updates RSS · CI watch RSS
- NanoBio Corporation portfolio CI